Candidemia Pipeline Insight Report 2023 (Updated) | Cidara Therapeutics, Scynexis, Inc., Amplyx Pharmaceuticals, Astellas Pharma Inc, Pfizer, Basilea Pharmaceutical, Vicuron Pharmaceuticals, and others

DelveInsight's "Candidemia Pipeline Insight 2023" report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in the Candidemia pipeline landscape. It covers the Candidemia pipeline drug profiles, including Candidemia clinical trials and nonclinical stage products. It also covers the Candidemia therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Recent Developmental Activities in the Candidemia Treatment Landscape
• On 23 March 2023, Rezafungin for injection, also known as REZZAYOTM, is now licensed by the U.S. Food and Drug Administration (FDA) as a treatment for candidemia and invasive candidiasis. The new medication is the first to be approved in more than ten years for the invasive fungal illness. It is a brand-new antifungal treatment administered intravenously once every week.
• In April 2022, the US FDA approved VIVJOA (oteseconazole) capsules, an azole antifungal indicated to reduce the incidence of recurrent vulvovaginal candidiasis (RVVC), also referred to as chronic yeast infection.
• In June 2021, the US FDA approved BREXAFEMME (ibrexafungerp) for the treatment of vulvovaginal candidiasis (VVC). It is a novel class of antifungal and the first and only oral fungicidal treatment that can cure a vaginal yeast infection in adults and postmenarchal pediatric patients. Recently, a supplemental New Drug Application (sNDA) to the US FDA of an additional indication i.e. for the prevention of recurrent vulvovaginal candidiasis (RVVC) was submitted.

Discover the recent breakthroughs happening in the Candidemia Pipeline landscape @ Candidemia Pipeline Outlook- https://www.delveinsight.com/report-store/candidemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Candidemia Pipeline Report
• DelveInsight's Candidemia pipeline report depicts a robust space with 4+ active players working to develop 4+ pipeline therapies for Candidemia treatment.
• The leading Candidemia Companies include Cidara Therapeutics, Scynexis, Inc., Amplyx Pharmaceuticals, Astellas Pharma Inc, Pfizer, Basilea Pharmaceutical, Vicuron Pharmaceuticals, and others
• Promising Candidemia Pipeline Therapies include ERAXIS (anidulafungin), Fosmanogepix, Rezafungin (CD101), Ibrexafungerp (SCY-078), CD101, APX001, Micafungin, fluconazole, Anidulafungin, Isavuconazole, Voriconazole, AmBisome, Fluconazole, Caspofungin, and others
• The Candidemia companies and academics are working to assess challenges and seek opportunities that could influence Candidemia R&D. The Candidemia therapies under development are focused on novel approaches to treat/improve Candidemia.

Candidemia Emerging Drugs Profile
• Rezafungin: Cidara Therapeutics
Cidara is developing a novel once-weekly echinocandin, rezafungin, for both the treatment and prevention of serious fungal infections, such as candidemia and invasive candidiasis. The structure and properties of rezafungin are specifically designed to improve upon a clinically validated mechanism, enhancing its efficacy and safety potential for patients. For the treatment of candidemia and invasive candidiasis, rezafungin has designations for Qualified Infectious Disease Product, or QIDP, Fast Track, and Orphan Drug. QIDP and Orphan Drug designations together provide a total of 12 years of marketing exclusivity in the United States from the time of FDA approval. Originally, this compound was owned by Seachaid Pharmaceuticals. Rezafungin acetate is now licensed by Mundipharma International and under the development of Cidara Therapeutics. The drug is currently being evaluated in Phase III stage of development for the treatment of patients with Candidemia.

Candidemia Segmentation: Phases
DelveInsight's report covers around 4+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Candidemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical
• Molecule Type

Products have been categorized under various Molecule types such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Get More Information on the Candidemia Drugs and Companies of Report @ Candidemia Ongoing Clinical Trials Analysis- https://www.delveinsight.com/sample-request/candidemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Candidemia Pipeline Report
• Coverage- Global
• Candidemia Companies- Cidara Therapeutics, Scynexis, Inc., Amplyx Pharmaceuticals, Astellas Pharma Inc, Pfizer, Basilea Pharmaceutical, Vicuron Pharmaceuticals, and others.
• Candidemia Pipeline Therapies- ERAXIS (anidulafungin), Fosmanogepix, Rezafungin (CD101), Ibrexafungerp (SCY-078), CD101, APX001, Micafungin, fluconazole, Anidulafungin, Isavuconazole, Voriconazole, AmBisome, Fluconazole, Caspofungin, and others.
• Candidemia Pipeline Segmentation: Product Type, Molecule Type, Route of Administration

Find out more about the list of FDA-approved drugs for Candidemia @ Candidemia Treatment Landscape- https://www.delveinsight.com/sample-request/candidemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. Candidemia: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Late Stage Products (Phase III)
7. Rezafungin: Cidara Therapeutics
8. Drug profiles in the detailed report…..
9. Mid Stage Products (Phase II)
10. APX001: Amplyx Pharmaceuticals
11. Drug profiles in the detailed report…..
12. Early stage products (Phase I)
13. Drug Name: Company Name
14. Drug profiles in the detailed report…..
15. Inactive Products
16. Candidemia Key Companies
17. Candidemia Key Products
18. Candidemia- Unmet Needs
19. Candidemia- Market Drivers and Barriers
20. Candidemia- Future Perspectives and Conclusion
21. Candidemia Analyst Views
22. Candidemia Key Companies
23. Appendix

Got Queries? Find out the related information on Candidemia Preclinical and Discovery Stage Products @ Candidemia Drugs, Unmet Needs, and Recent Trends- https://www.delveinsight.com/sample-request/candidemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Company Name: DelveInsight
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: +91 9568243403
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.